Nefiracetam is a racetam investigated for neurological symptoms, including apathy after stroke. The research below distinguishes observed findings from interpretation.[1.1]
Selected human research: 13 patients randomized in a double-blind trial to nefiracetam 900 mg daily or placebo for 12 weeks. Route is not specified in the abstract. The primary apathy outcome did not differ significantly between groups at 12 weeks. The authors identify the very small randomized sample as the main limitation. This null trial does not prove equivalence, and it does not support healthy-person enhancement. The authors identify the very small randomized sample as the main limitation. This null trial does not prove equivalence, and it does not support healthy-person enhancement.[2.1]
Studied methods, not dosing advice. Selected evidence, not a complete literature review or formal quality appraisal.
No completed study summaries are linked to this compound page yet. This is a coverage gap on PED Evidence, not evidence that human studies or other research do not exist.
13 patients randomized in a double-blind trial to nefiracetam 900 mg daily or placebo for 12 weeks. Route is not specified in the abstract.
Demonstrated findings
The primary apathy outcome did not differ significantly between groups at 12 weeks.
Limitations & adverse findings
The authors identify the very small randomized sample as the main limitation. This null trial does not prove equivalence, and it does not support healthy-person enhancement.
What might this mean? · interpretation
These findings apply to the population and methods described above.
What might this mean, and what would change the interpretation?
The authors identify the very small randomized sample as the main limitation. This null trial does not prove equivalence, and it does not support healthy-person enhancement.
What would clarify this: Independent replication with clinically meaningful outcomes and longer safety follow-up.
Findings reviewed · abstract
Checked Sep 23, 2026 against the linked abstract. This reading note is not a formal risk-of-bias appraisal.
More about Nefiracetam: identity, safety & reference details
Small moleculeBrain & cognition
Primary research area
Neurological & cognitive research
Regulatory status
See compound-specific sources
Evidence level
Human research · indication-specific
Primary mechanism
See the source-linked compound overview
Reference profile available · Coverage varies by section
What has been observed?
Selected source-linked reading notes, not the complete literature or a pooled conclusion.
Human · Abstract reviewed
Nefiracetam: what does this study show?
13 patients randomized in a double-blind trial to nefiracetam 900 mg daily or placebo for 12 weeks. Route is not specified in the abstract.
The primary apathy outcome did not differ significantly between groups at 12 weeks.
Limits & adverse findings: The authors identify the very small randomized sample as the main limitation. This null trial does not prove equivalence, and it does not support healthy-person enhancement. The authors identify the very small randomized sample as the main limitation. This null trial does not prove equivalence, and it does not support healthy-person enhancement.
The research below distinguishes observed findings from interpretation. [1]
Known half-life
No source-verified value in this profile yet. A treatment schedule or duration of an effect is not a drug half-life.
Half-life describes how quickly the measured drug concentration falls by half. It does not set a dosing interval.
Evidence & important limits
The authors identify the very small randomized sample as the main limitation. This null trial does not prove equivalence, and it does not support healthy-person enhancement. [1]
Safety & evidence boundaries
Source-specific information, not a personal safety clearance or monitoring plan.
The authors identify the very small randomized sample as the main limitation. This null trial does not prove equivalence, and it does not support healthy-person enhancement.
Human study: The authors identify the very small randomized sample as the main limitation. This null trial does not prove equivalence, and it does not support healthy-person enhancement. Source
Explore safety questions by system
These are literature filters, not claims that this compound causes each effect. A keyword match is not a confirmed adverse reaction.
Interactions, rare harms, long-term effects and reversibility require separate evidence. Do not infer they are absent when the sources here do not address them.
Identity, names & formulations
Canonical compound: Nefiracetam · nefiracetam
No additional aliases recorded.
Names share a parent research page. Different esters, salts, routes and brands are not assumed to have the same half-life, indication or exposure.
Combination evidence stays attached to the studied combination. It is not automatically assigned to each ingredient.
Understand the evidence types
Read the model and design first, then the population, outcome and limitations. These categories describe evidence, not a best-compound ranking.
Randomized human trials
Compare assigned interventions. Randomization does not by itself establish low bias or relevance to every population.
Controlled human studies
Use a comparison group; allocation and confounding still matter.
Prospective human research
Follows participants forward. It may be observational or interventional, so this is not a separate quality grade.
Observational human research
Describes associations. Confounding can explain differences.
Case reports and series
Useful for unusual events and safety signals, not reliable rates or effect sizes.
Animal research
Can test biology and function in a living model. Human exposure, benefit and safety remain separate questions.
Cell and tissue research
Tests responses in a preparation, including human-derived cells. It is not a human participant trial.
Mechanistic and computational evidence
Helps explain or predict a pathway; predictions need experimental and clinical testing.
Anecdotal reports
Self-reported experiences can generate questions. Product identity, selection bias and other interventions may be uncontrolled.
Systematic reviews synthesize studies and depend on their quality. Preprint status and abstract versus full-paper reading are separate labels. Citation popularity measures attention, not reliability. A study summary is not a formal quality appraisal.
Reference facts checked 2026-09-23. Source scope is listed above; this is not a formal quality appraisal. See each label for full prescribing information.